Entera Bio (ENTX)

Company Profile

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.

Company profile

Ticker

ENTX, ENTXW

Exchange

NASDAQ

Website

www.enterabio.com

CEO

Adam Gridley

Incorporated

Israel

Location

Israel

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

SEC CIK

0001638097

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Entera Bio Inc. ...

ENTX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

10 Nov 22

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Submission of Matters to a Vote of Security Holders

9 Sep 22

424B5

Prospectus supplement for primary offering

2 Sep 22

8-K

Entry into a Material Definitive Agreement

11 Aug 22

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

11 Aug 22

8-K

Entera Bio Corporate PresentationAugust 2022

1 Aug 22

Transcripts

View all

ENTX

Earnings call transcript

2022 Q1

18 May 22

ENTX

Earnings call transcript

2021 Q4

8 Mar 22

ENTX

Earnings call transcript

2021 Q2

16 Aug 21

ENTX

Earnings call transcript

2020 Q4

18 Mar 21

ENTX

Earnings call transcript

2020 Q3

19 Nov 20

ENTX

Earnings call transcript

2020 Q2

20 Aug 20

ENTX

Earnings call transcript

2020 Q1

21 May 20

ENTX

Earnings call transcript

2019 Q4

26 Mar 20

ENTX

Earnings call transcript

2019 Q3

21 Nov 19

ENTX

Earnings call transcript

2019 Q2

20 Aug 19

Latest ownership filings

View all

Miranda Jayne Toledano

Miranda Jayne Toledano

9 Sep 22

Financial summary

Financial statements Chart ENTX financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	14.39 mm	14.39 mm	14.39 mm	14.39 mm		14.39 mm
Cash burn (monthly)	975.33 k	881.17 k	957.67 k	1.17 mm		399.33 k
Cash used (since last report)	2.24 mm	2.02 mm	2.20 mm	2.69 mm		917.56 k
Cash remaining	12.15 mm	12.37 mm	12.19 mm	11.70 mm		13.47 mm
Runway (months of cash)	12.5	14.0	12.7	10.0		33.7

Beta Read what these cash burn values mean

Financial data from Entera Bio earnings reports.

Institutional ownership, Q3 2022

ENTX institutional ownership history Ownership history

8.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	13	-92.3%
Opened positions	0	0
Closed positions	12	2	+500.0%
Increased positions	1	1	–
Reduced positions	0	5	EXIT

13F shares	Current	Prev Q	Change
Total value	3.24 mm	9.72 mm	-66.7%
Total shares	2.40 mm	6.06 mm	-60.4%
Total puts	0.00	0.00
Total calls	0.00	152.90 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Centillion Fund	2.40 mm	$3.24 mm	+111.9%

Largest transactions	Shares	Bought/sold	Change
Knoll Capital Management	0.00	-2.48 mm	EXIT
Ra Capital Management	0.00	-2.35 mm	EXIT
Centillion Fund	2.40 mm	+1.27 mm	+111.9%
Geode Capital Management	0.00	-17.60 k	EXIT
Millennium Management	0.00	-16.87 k	EXIT
Citadel Advisors	0.00	-12.66 k	EXIT
Altium Wealth Management	0.00	-11.83 k	EXIT
Virtu Financial	0.00	-10.88 k	EXIT
PNC PNC Financial Services	0.00	-10.00 k	EXIT
UBS UBS Group AG - Registered Shares	0.00	-7.40 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ENTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Nov 22	Lieberman Gerald M	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	Yes	No	0.59	4,000	2.36 k	6,200
14 Nov 22	Lieberman Gerald M	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	Yes	No	0.56	4,000	2.24 k	6,200
14 Nov 22	Lieberman Gerald M	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	Yes	No	0.56	4,000	2.24 k	6,200
14 Nov 22	Lieberman Gerald M	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	Yes	No	0.56	4,000	2.24 k	6,200
14 Nov 22	Lieberman Gerald M	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	No	No	0.57	34,000	19.38 k	194,209
14 Nov 22	Dana Yaacov-Garbeli	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	Yes	No	0.536	26,580	14.25 k	56,580
11 Nov 22	Miranda Jayne Toledano	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	No	No	0.5317	50,000	26.58 k	56,800
11 Nov 22	Sean Ellis	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	No	No	0.53	30,000	15.90 k	62,100
11 Nov 22	Dana Yaacov-Garbeli	Ordinary Shares, par value NIS 0.0000769 per share	Buy	Acquire P	Yes	No	0.52	30,000	15.60 k	30,000
7 Sep 22	Dana Yaacov-Garbeli	Stock Option Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	2.86	35,000	100.10 k	35,000